XBiotech (XBIT) Other Non-Current Assets (2014 - 2015)
XBiotech (XBIT) posted Other Non-Current Assets of $1.0 million for Q1 2015, up 219.75% on a QoQ basis from $324000.0 in Q4 2014.
Powered by 
Analysis
XBiotech (XBIT) Other Non-Current Assets (2014 - 2015) Analysis & Trends
XBiotech has reported Other Non-Current Assets for 2 years, with the latest figure at $1.0 million in Q1 2015.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $1.0 million in Q1 2015; TTM through Mar 2015 was $1.0 million, a N/A change from a year earlier, with the FY2014 full-year figure at $324000.0, changed N/A from the prior year.
- Other Non-Current Assets was $1.0 million for Q1 2015 at XBiotech, up from $324000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.0 million in Q1 2015, with the low at $324000.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 29.59 Mn |
| 10 | XBiotech | 66.16 Mn | 66.16 Mn | - | - |